Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 1.
doi: 10.1097/HEP.0000000000001334. Online ahead of print.

Getting to HBV cure-Will new biomarkers help?

Jordan J Feld  1 , Adam J Gehring  1   2 , Fabien Zoulim  3
Affiliations

Getting to HBV cure-Will new biomarkers help?

Jordan J Feld et al. Hepatology. .

Abstract

The natural history and response to therapy in chronic hepatitis B (CHB) infection have been defined by a combination of serological and virological biomarkers along with liver biochemistry and/or histology. A number of novel biomarkers, including HBV RNA, hepatitis B core-related antigen, hepatitis B core antigen, and quantitative HBsAg, have been developed and evaluated in different clinical settings. Novel immunological biomarkers have also been studied but have been less well characterized. In addition to providing insights into HBV biology, these novel biomarkers may significantly aid in the design, development, and assessment of novel antiviral strategies aiming for the cure of chronic hepatitis B. Biomarkers can be used to confirm the mechanism of action or target engagement of a novel agent but also may be used for patient selection for trials and clinical use. Ideally, biomarkers can be used to more accurately define stages of chronic hepatitis B, particularly degrees of virological control. In this review, the serological, virological, and immunological biomarkers are described with a focus on how they can be used to guide the development of HBV cure strategies. New terminology is proposed for clinical endpoints, including sustained control to replace the concept of partial cure and resolved chronic infection to replace functional cure, reserving the term cure for clearance or silencing of all covalently closed circular DNA and integrated HBV DNA.

Keywords: HBV RNA; HBcrAg; hepatitis B RNA; hepatitis B core-related antigen; qHBsAg; quantitative HBsAg; resolved chronic infection; sustained control.

PubMed Disclaimer

References

    1. European Association for the Study of the L. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol, 2017 67:370–398.
    1. Kramvis A, Chang KM, Dandri M, Farci P, Glebe D, Hu J, et al. A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook. Nat Rev Gastroenterol Hepatol. 2022;19:727–745.
    1. Charre C, Levrero M, Zoulim F, Scholtes C. Non-invasive biomarkers for chronic hepatitis B virus infection management. Antiviral Res. 2019;169:104553.
    1. Likhitsup A, Lok AS. Understanding the natural history of hepatitis B virus infection and the new definitions of cure and the endpoints of clinical trials. Clin Liver Dis. 2019;23:401–416.
    1. Ghany MG, Buti M, Lampertico P, Lee HM; Faculty A-EH-HTEC. Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference. Hepatology. 2023;78:1654–1673.

LinkOut - more resources